The NM_000329.3(RPE65):c.106del (p.Leu36SerfsTer?) variant introduces a premature stop codon into exon 3 of 14, and is predicted to lead to nonsense-mediated decay in a gene in which loss-of-function is an established mechanism of disease (PVS1). This variant is present in gnomAD v.4.1.0 at an allele frequency of 8.474e-7 , with 1 allele / 1180032 total alleles in the European (non-Finnish) population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting).This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who harbored the variant in the compound heterozygous state (confirmed in trans) with a Pathogenic variant previously classified by the LCA/eoRD VCEP (1 pt, PM3)(PMID: 33308271). At least one proband harboring this variant exhibits a phenotype including a diagnosis of LCA (0.5 pts) with nystagmus (1 pt), myopia, retinal degeneration at 2-years-old (1 pt), sluggish pupillary responses (0.5 pts), extensive atrophic retinal changes, salt and pepper fundus appearance (2 pts), optic disc pallor, and extinguished rod and cone ERG (1.5 pts). Screening by NGS did not reveal any additional variants of interest (2 pts). Together these phenotypes are highly specific for RPE65-related recessive retinopathy (total 8.5 points, PMID: 33308271, PP4_Moderate).The variant has been reported to segregate with childhood-onset severe retinal dystrophy through the proband plus 1 similarly affected relative, with the variant present in the compound heterozygous state (PP1; PMID: 33308271).In summary, this variant meets the criteria to be classified as Pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PVS1, PM2_supporting, PP4_moderate, PP1, PM3. (VCEP specifications version 1.0.0; date of approval 09/21/2023).